$0.60
-0.01 (-1.39%)
Open$0.60
Previous Close$0.61
Day High$0.67
Day Low$0.56
52W High$4.35
52W Low$0.63
Volume—
Avg Volume174.1K
Market Cap18.36M
P/E Ratio—
EPS$-3.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,977.3% upside
Current
$0.60
$0.60
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.72M | 26.98M | 10.25M |
| Net Income | -106,119,077 | -83,866,499 | 2.27M |
| Profit Margin | -345.5% | -328.2% | 22.1% |
| EBITDA | -82,608,144 | -68,912,659 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +13.9% | +13.9% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |